Medpace president exercises options, sells 31,707 shares

Medpace Holdings, Inc. President Jesse J. Geiger exercised stock options and sold the resulting shares.

Rhea-AI Filing Summary

Medpace Holdings, Inc. President Jesse J. Geiger exercised stock options and sold the resulting shares. He exercised options for 31,707 shares of common stock at an exercise price of $138.87 per share, then sold 31,707 shares in an open-market transaction at a weighted average price of $455.30 per share. Following these transactions, he holds 15,000 shares of Medpace common stock directly. The filing notes that the option vested in full on February 15, 2026 and that the sale price reflects multiple trades between $451.36 and $460.288 per share.

Insider Trade Summary

Exercise and Sale: 31,707 shares ($10.03M approx. pre-tax spread)

Exercise and Sale 3 txns

Insider GEIGER JESSE J

Role President

Sold 31,707 shs ($14.44M)

Approx. gross sale proceeds $14.44M

Approx. exercise cost $4.40M

Approx. pre-tax spread $10.03M

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (Right to Buy)	31,707	$0.00	$0.00
Exercise	Common Stock	31,707	$138.87	$4.40M
Sale	Common Stock	31,707	$455.30	$14.44M

Holdings After Transaction: Employee Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 15,000 shares (Direct)

Footnotes (2)

1. F1. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $451.36 to $460.288. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
2. F2. The option vested in full on February 15, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Medpace (MEDP) President Jesse Geiger report in this Form 4?

Jesse Geiger reported an option exercise and share sale. He exercised options for 31,707 Medpace shares at $138.87 and sold 31,707 shares at a weighted average of $455.30, leaving him with 15,000 shares owned directly after the transactions.

How many Medpace (MEDP) shares did Jesse Geiger sell and at what price?

He sold 31,707 Medpace common shares in the open market. The weighted average sale price was $455.30 per share, across multiple trades with individual prices ranging from $451.36 to $460.288, as disclosed in the Form 4 footnote.

What options did Jesse Geiger exercise in the latest Medpace (MEDP) Form 4?

He exercised employee stock options covering 31,707 Medpace common shares. The exercise price was $138.87 per share, and the filing states the option vested in full on February 15, 2026, after which the options were fully exercised and no longer outstanding.

How many Medpace (MEDP) shares does Jesse Geiger own after these transactions?

After exercising options and selling shares, Jesse Geiger directly owns 15,000 Medpace common shares. The Form 4 lists this amount as his total direct holdings following the reported transactions on March 17, 2026, providing context for the scale of the activity.

Was the Medpace (MEDP) share sale by Jesse Geiger a market transaction?

Yes. The Form 4 labels the 31,707-share disposition as an open-market sale. It specifies transaction code “S” and describes it as a sale in open market or private transaction, with a weighted average sale price of $455.30 per share across multiple trades.

Does Jesse Geiger have remaining Medpace (MEDP) stock options after this Form 4?

The filing shows the reported option position going to zero after exercise. He exercised 31,707 options that vested on February 15, 2026 and received the same number of shares, indicating this particular option grant was fully exercised and no longer outstanding.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/19/2026 - 04:45 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GEIGER JESSE J

(Last) (First) (Middle)

C/O MEDPACE HOLDINGS, INC.

5375 MEDPACE WAY

(Street)

CINCINNATI OHIO 45227

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medpace Holdings, Inc. [ MEDP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/17/2026		M		31,707	A	$138.87	46,707	D
Common Stock	03/17/2026		S		31,707	D	$455.3(1)	15,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$138.87	03/17/2026		M			31,707	(2)	08/15/2027	Common Stock	31,707	$0	0	D

Explanation of Responses:

1. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $451.36 to $460.288. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

2. The option vested in full on February 15, 2026.

Remarks:

	/s/ Stephen P. Ewald, Attorney-in-Fact for Jesse J. Geiger	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)